|

Coronavirus: Oxford/AstraZeneca Phase 1/2 trial shows safe, immunogenic vaccine, S&P 500 positive

The Lancet published the results of the University of Oxford's Phase 1/2 in a vaccine trial. The editor of the highly regarded medical publication has tweeted that the vaccine is safe, well-tolerated, and immunogenic.  

The research is done in collaboration with AstraZeneca and the UK secured around 90 million doses of the candidate, ahead of a broader trial. Apart from creating antibodies, it also triggers the creation of T-cells. This development was previously described as "double-protection." 

-- more to come

Administering the vaccine candidate triggered antibody responses in 32/35 (91%) participants after a single dose. After a booster dose, all participants had neutralizing activity. 

The S&P 500 has turned positive after kicking off marginally lower at the beginning of a new trading week. Moderna and Pfizer/NioNTech. 

Author

Yohay Elam

Yohay Elam

FXStreet

Yohay is in Forex since 2008 when he founded Forex Crunch, a blog crafted in his free time that turned into a fully-fledged currency website later sold to Finixio.

More from Yohay Elam
Share:

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

By subscribing you agree to our Terms and conditions.

Editor's Picks

EUR/USD tests 1.1800, closes in on a fresh two-month high

EUR/USD extends its gains for the second consecutive day on Tuesday and trades near 1.1800. The broad-based US Dollar weakness and a potential policy divergence between the European Central Bank and the Federal Reserve keep the bullish bias intact heading into the holiday season.

GBP/USD climbs above 1.3500 area, renews 11-week peak

GBP/USD extends its weekly rally and trades at its highest level since early October above 1.3500. The US Dollar remains under persistent bearish pressure heading into the Christmas break, while Pound traders largely brush off the latest interest rate cut from the Bank of England.

Gold approaches $4,500 as record-setting rally continues

Gold builds on Monday's impressive gains and advances toward $4,500, setting fresh record-highs along the way. Heightened geopolitical tensions, combined with the ongoing US Dollar (USD) selloff ahead of the Q3 GDP data, help XAU/USD preserve its bullish momentum.

US GDP expected to highlight steady growth in Q3

The United States Bureau of Economic Analysis (BEA) will publish the first preliminary estimate of the third-quarter Gross Domestic Product on Tuesday, at 13:30 GMT. Analysts expect the data to show annualized growth of 3.2%, following the 3.8% expansion in the previous quarter.

Ten questions that matter going into 2026

2026 may be less about a neat “base case” and more about a regime shift—the market can reprice what matters most (growth, inflation, fiscal, geopolitics, concentration). The biggest trap is false comfort: the same trades can look defensive… right up until they become crowded.

XRP steadies above $1.90 support as fund inflows and retail demand rise

Ripple (XRP) is stable above support at $1.90 at the time of writing on Monday, after several attempts to break above the $2.00 hurdle failed to materialize last week. Meanwhile, institutional interest in the cross-border remittance token has remained steady.